News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: r622102675 post# 205657

Sunday, 02/08/2015 6:55:02 PM

Sunday, February 08, 2015 6:55:02 PM

Post# of 347009
I actually just found a post and not sure if all these names are still involved or not...it seems someone related to one of the parties has had an incentive to make sure it was delayed

Plaintiffs in the Class Action: James T. Fahey (Highest Financial Stake)

The plaintiffs are:

(1) James T. Fahey
(2) Marshall Lee
(3) Jason Ebach and Mary Legnetti (“Ebach & Legnetti”)
(4) Allan L. Tereshko, Edward Buzz Bradley, and Edward Arduino (“Tereshko Investors Group”).

Tereskho Investors Group has also concluded that it does not have the largest financial stake in the outcome of the litigation, but has stated that the group remains willing to serve as lead plaintiff if the presumptive plaintiff is found to be an inadequate representative. Lucas, the Lewis Movants, and the Tereshko Investors Group have identified Fahey as the movant with the highest financial stake in the litigation.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92348539



Interesting Read about the Class Action Law suit:

Fahey asserts that he purchased 439,000 shares of common stock in Peregrine securities during the class period by expending $1,074,933.46 in net expenditures.

Fahey additionally asserts that he purchased 8,645 option contracts for Peregrine securities and expended $775,360 for purchase of those options.

Finally, Fahey asserts that he suffered a loss of $375,269.78 as a result of Peregrine’s misrepresentations.


http://investorshub.advfn.com/boards/replies.aspx?msg=92348575




Great, he's a judge:

pview.findlaw.com/view/1788064_1


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92348575




----------------------------------------------------------

If this is the same Allan L. Tereshko and one in the same judge, soon after Sept 2012 he was removed

http://www.thelegalintelligencer.com/id=1202576329138/Tereshko-Resigns-as-Supervising-Judge-in-Wake-of-Critical-Superior-Court-Decision?slreturn=20150108184841


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y